<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32000838</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers.</ArticleTitle><Pagination><StartPage>7</StartPage><MedlinePgn>7</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-020-0359-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">A repeat expansion in the C9orf72-SMCR8 complex subunit (C9orf72) is the most common genetic cause of two debilitating neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Currently, much remains unknown about which variables may modify these diseases. We sought to investigate associations between C9orf72 promoter methylation, RNA expression levels, and repeat length, their potential effects on disease features, as well as changes over time and within families.</AbstractText><AbstractText Label="METHODS">All samples were obtained through the ALS Center at Mayo Clinic Florida. Our primary cohort included 75 unrelated patients with an expanded C9orf72 repeat, 33 patients who did not possess this expansion, and 20 control subjects without neurodegenerative diseases. Additionally, 67 members from 17 independent C9orf72 families were selected of whom 33 harbored this expansion. Longitudinally collected samples were available for 35 C9orf72 expansion carriers. To increase our understanding of C9orf72-related diseases, we performed quantitative methylation-sensitive restriction enzyme-based assays, digital molecular barcoding, quantitative real-time PCR, and Southern blotting.</AbstractText><AbstractText Label="RESULTS">In our primary cohort, higher methylation levels were observed in patients with a C9orf72 repeat expansion than in patients without this expansion (p&#x2009;=&#x2009;1.7e-13) or in control subjects (p&#x2009;=&#x2009;3.3e-07). Moreover, we discovered that an increase in methylation levels was associated with a decrease in total C9orf72 transcript levels (p&#x2009;=&#x2009;5.5e-05). These findings aligned with our observation that C9orf72 expansion carriers had lower expression levels of total C9orf72 transcripts than patients lacking this expansion (p&#x2009;=&#x2009;3.7e-07) or control subjects (p&#x2009;=&#x2009;9.1e-05). We also detected an elevation of transcripts containing intron 1a (upstream of the repeat) in patients carrying a C9orf72 repeat expansion compared to (disease) controls (p&#x2009;&#x2264;&#x2009;0.01), an indication of abortive transcripts and/or a switch in transcription start site usage. While methylation and expression levels were relatively stable over time, fluctuations were seen in repeat length. Interestingly, contractions occurred frequently in parent-offspring transmissions (&gt;&#x2009;50%), especially in paternal transmissions. Furthermore, smaller repeat lengths were detected in currently unaffected individuals than in affected individuals (p&#x2009;=&#x2009;8.9e-04) and they were associated with an earlier age at collection (p&#x2009;=&#x2009;0.008).</AbstractText><AbstractText Label="CONCLUSIONS">In blood from C9orf72 expansion carriers, we found elevated methylation levels, reduced expression levels, and unstable expansions that tend to contract in successive generations, arguing against anticipation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Jazmyne L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finch</LastName><ForeName>NiCole A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kachergus</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeJesus-Hernandez</LastName><ForeName>Mariely</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christopher</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudencio</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heckman</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>E Aubrey</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Jaimin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. Rademakers.Rosa@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Blitterswijk</LastName><ForeName>Marka</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3054-7053</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. VanBlitterswijk.Marka@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097261</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS099631</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097273</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS099114</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097261</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS099631</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Anticipation</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">Expansion size</Keyword><Keyword MajorTopicYN="N">Hypermethylation</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Paternal contraction</Keyword><Keyword MajorTopicYN="N">Repeat expansion disorder</Keyword></KeywordList><CoiStatement>MDJ and RR hold a patent on methods to screen for the hexanucleotide repeat expansion in the <i>C9orf72</i> gene. No other competing interests were declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32000838</ArticleId><ArticleId IdType="pmc">PMC6993399</ArticleId><ArticleId IdType="doi">10.1186/s13024-020-0359-8</ArticleId><ArticleId IdType="pii">10.1186/s13024-020-0359-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, Caulfield T, Daughrity L, Dunmore JH, Castanedes-Casey M, Chew J, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 2013;126:829&#x2013;844. doi: 10.1007/s00401-013-1192-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1192-8</ArticleId><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW, 3rd, Rademakers R, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646. doi: 10.1016/j.neuron.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338. doi: 10.1126/science.1232927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Arzberger T, Grasser FA, Gijselinck I, May S, Rentzsch K, Weng SM, Schludi MH, van der Zee J, Cruts M, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013;126:881&#x2013;893. doi: 10.1007/s00401-013-1189-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1189-3</ArticleId><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Banez-Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013;110:E4968&#x2013;E4977. doi: 10.1073/pnas.1315438110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1315438110</ArticleId><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zinman L, Moreno D, Schymick J, Liang Y, Sato C, Zheng Y, Ghani M, Dib S, Keith J, et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet. 2013;92:981&#x2013;989. doi: 10.1016/j.ajhg.2013.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.04.017</ArticleId><ArticleId IdType="pmc">PMC3675239</ArticleId><ArticleId IdType="pubmed">23731538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Rainero I, Rubino E, Pinessi L, Bruni AC, Maletta RG, Nacmias B, Sorbi S, Galimberti D, Surace EI, et al. Hypermethylation of the CpG-island near the C9orf72 G(4)C(2)-repeat expansion in FTLD patients. Hum Mol Genet. 2014;23:5630&#x2013;5637. doi: 10.1093/hmg/ddu279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu279</ArticleId><ArticleId IdType="pubmed">24908669</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Russ J, Wu K, Neal D, Suh E, McNally AG, Irwin DJ, Van Deerlin VM, Lee EB. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathol. 2014;128:525&#x2013;541. doi: 10.1007/s00401-014-1286-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1286-y</ArticleId><ArticleId IdType="pmc">PMC4161616</ArticleId><ArticleId IdType="pubmed">24806409</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ J, Liu EY, Wu K, Neal D, Suh E, Irwin DJ, McMillan CT, Harms MB, Cairns NJ, Wood EM, et al. Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol. 2015;129:39&#x2013;52. doi: 10.1007/s00401-014-1365-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1365-0</ArticleId><ArticleId IdType="pmc">PMC4282973</ArticleId><ArticleId IdType="pubmed">25388784</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C, Barbier M, Camuzat A, Anquetil V, Lattante S, Clot F, Cazeneuve C, Rinaldi D, Couratier P, Deramecourt V, et al. Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers. Neurobiol Aging. 2019;74:234 e231&#x2013;234 e238. doi: 10.1016/j.neurobiolaging.2018.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.09.010</ArticleId><ArticleId IdType="pubmed">30337192</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, Campbell T, Uphill J, Borg A, Fratta P, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet. 2013;92:345&#x2013;353. doi: 10.1016/j.ajhg.2013.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.01.011</ArticleId><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Dejesus-Hernandez M, Niemantsverdriet E, Murray ME, Heckman MG, Diehl NN, Brown PH, Baker MC, Finch NA, Bauer PO, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 2013;12:978&#x2013;988. doi: 10.1016/S1474-4422(13)70210-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70210-2</ArticleId><ArticleId IdType="pmc">PMC3879782</ArticleId><ArticleId IdType="pubmed">24011653</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O, Garcia-Redondo A, Rojas-Garcia R, Sanchez-Valle R, Noguera A, Gomez-Tortosa E, Pastor P, Hernandez I, Esteban-Perez J, Suarez-Calvet M, et al. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Hum Mol Genet. 2014;23:749&#x2013;754. doi: 10.1093/hmg/ddt460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt460</ArticleId><ArticleId IdType="pubmed">24057670</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin A, Akimoto C, Wuolikainen A, Alstermark H, Jonsson P, Birve A, Marklund SL, Graffmo KS, Forsberg K, Brannstrom T, Andersen PM. Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Hum Mol Genet. 2015;24:3133&#x2013;3142. doi: 10.1093/hmg/ddv064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv064</ArticleId><ArticleId IdType="pubmed">25712133</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh E, Lee EB, Neal D, Wood EM, Toledo JB, Rennert L, Irwin DJ, McMillan CT, Krock B, Elman LB, et al. Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathol. 2015;130:363&#x2013;372. doi: 10.1007/s00401-015-1445-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1445-9</ArticleId><ArticleId IdType="pmc">PMC4545720</ArticleId><ArticleId IdType="pubmed">26022924</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Engelborghs S, De Bleecker J, Ivanoiu A, Deryck O, Edbauer D, Zhang M, et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol Psychiatry. 2016;21:1112&#x2013;1124. doi: 10.1038/mp.2015.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.159</ArticleId><ArticleId IdType="pmc">PMC4960451</ArticleId><ArticleId IdType="pubmed">26481318</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Gendron TF, Baker MC, DeJesus-Hernandez M, Finch NA, Brown PH, Daughrity LM, Murray ME, Heckman MG, Jiang J, et al. Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathol. 2015;130:863&#x2013;876. doi: 10.1007/s00401-015-1480-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1480-6</ArticleId><ArticleId IdType="pmc">PMC4655160</ArticleId><ArticleId IdType="pubmed">26437865</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EA, Shaw PG, Kim MS, Maragakis NJ, Troncoso JC, Pandey A, Sattler R, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507:195&#x2013;200. doi: 10.1038/nature13124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13124</ArticleId><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzu P, Blauwendraat C, Heetveld S, Lynes EM, Castillo-Lizardo M, Dhingra A, Pyz E, Hobert M, Synofzik M, Simon-Sanchez J, et al. C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers. Acta Neuropathol Commun. 2016;4:37. doi: 10.1186/s40478-016-0306-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0306-7</ArticleId><ArticleId IdType="pmc">PMC4832459</ArticleId><ArticleId IdType="pubmed">27079381</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick P, Zhang M, van Blitterswijk M, Sato C, Moreno D, Xiao S, Zhang AB, McKeever PM, Weichert A, Schneider R, et al. Unaffected mosaic C9orf72 case: RNA foci, dipeptide proteins, but upregulated C9orf72 expression. Neurology. 2018;90:e323&#x2013;e331. doi: 10.1212/WNL.0000000000004865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004865</ArticleId><ArticleId IdType="pmc">PMC5798652</ArticleId><ArticleId IdType="pubmed">29282338</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zhang M, Bruni AC, Maletta RG, Colao R, Fratta P, Polke JM, Sweeney MG, Mudanohwo E, Nacmias B, et al. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathol. 2015;129:715&#x2013;727. doi: 10.1007/s00401-015-1401-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1401-8</ArticleId><ArticleId IdType="pubmed">25716178</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali CP, Patino M, Tai YK, Ho WY, McLean CA, Morris CM, Seeley WW, Miller BL, Gaig C, Vonsattel JPG, et al. C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathol. 2019;138:795&#x2013;811. doi: 10.1007/s00401-019-02045-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02045-5</ArticleId><ArticleId IdType="pmc">PMC6802287</ArticleId><ArticleId IdType="pubmed">31327044</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Polke JM, Newcombe J, Mizielinska S, Lashley T, Poulter M, Beck J, Preza E, Devoy A, Sidle K, et al. Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion. Neurobiol Aging. 2015;36:546 e541&#x2013;546 e547. doi: 10.1016/j.neurobiolaging.2014.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.07.037</ArticleId><ArticleId IdType="pmc">PMC4270445</ArticleId><ArticleId IdType="pubmed">25179228</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper PS, Harley HG, Reardon W, Shaw DJ. Anticipation in myotonic dystrophy: new light on an old problem. Am J Hum Genet. 1992;51:10&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1682874</ArticleId><ArticleId IdType="pubmed">1609789</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Gijselinck I, Sleegers K, De Bleecker J, Sieben A, Vandenberghe R, Van Langenhove T, Baets J, Deryck O, et al. Clinical evidence of disease anticipation in families segregating a C9orf72 repeat expansion. JAMA Neurol. 2017;74:445&#x2013;452. doi: 10.1001/jamaneurol.2016.4847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.4847</ArticleId><ArticleId IdType="pubmed">28192553</ArticleId></ArticleIdList></Reference><Reference><Citation>Monros E, Molto MD, Martinez F, Canizares J, Blanca J, Vilchez JJ, Prieto F, de Frutos R, Palau F. Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat. Am J Hum Genet. 1997;61:101&#x2013;110. doi: 10.1086/513887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/513887</ArticleId><ArticleId IdType="pmc">PMC1715858</ArticleId><ArticleId IdType="pubmed">9245990</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>